<DOC>
	<DOCNO>NCT00041054</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Exisulind may make tumor cell sensitive chemotherapy . Combining chemotherapy exisulind may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy exisulind treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Exisulind Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine percentage patient extensive stage small cell lung cancer live 12 month treatment carboplatin , etoposide , exisulind . - Determine response rate patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive carboplatin IV 30 minute day 1 etoposide IV 30-60 minute day 1-3 . Patients also receive oral exisulind twice daily day 1-21 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year every 4 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Sulindac sulfone</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan Lesions consider nonmeasurable include : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion situate previously irradiate area Must consider combined chemotherapy radiotherapy No active CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST great 2 time ULN No clinically significant hepatic disease Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min No clinically significant renal disease Cardiovascular : No clinically significant cardiac disease Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent uncontrolled illness No known sensitivity sulindac PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy small cell lung cancer No concurrent chemotherapy Endocrine therapy : No concurrent hormonal agent except : Steroids adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy , include palliation No concurrent radiotherapy Surgery : Not specify Other : More 7 day since prior sulindac No concurrent sulindac</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>